Figure 4.

Comparison of different anti-TNF biotherapies. Healthy activated-PBMC were pre-incubated or not with two doses of anti-TNF biotherapies, 10 μg/ml or 100 μg/ml and cocultured with RA synoviocytes at a ratio 5:1 for 48 h. Infliximab, Etanercept, and Adalimumab were compared. After 48 h, the production of IL-17, IL-6, IL-1β, IFN-γ, and IL-10 in cell supernatants was measured by ELISA. *^,#p ≤ 0.05. *Compares anti-TNF vs. control and ^#compares the different anti-TNF. Results are represented as mean ± SEM, n = 10 experiments from six different RA patients.